NRD
ARQT icon

Nebula Research & Development’s Arcutis Biotherapeutics ARQT Stock Holding History

Nebula Research & Development’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,100
Closed -$110K – 797
2024
Q1 		$110K Buy
+11,100
New +$82.8K 0.02% 686
2023
Q2 		– Sell
-25,976
Closed -$286K – 339
2023
Q1 		$286K Buy
+25,976
New +$376K 0.5% 117

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nebula Research & Development's ARQT Position: Q2 2024 in Review

Nebula Research & Development sold out of Arcutis Biotherapeutics (ARQT) in Q2 2024, closing a stake of 11,100 shares — an estimated $110K sold.

Nebula Research & Development first reported a position in ARQT in Q1 2023 and held it in 2 quarters. The position peaked at $286K in Q1 2023. 186 funds tracked by Wall St. Rank hold ARQT as of Q2 2024.

  • Nebula Research & Development reported no remaining Arcutis Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 11,100 Arcutis Biotherapeutics shares in Q2 2024, an estimated $110K.
  • Nebula Research & Development first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 2 quarters.
  • Nebula Research & Development's Arcutis Biotherapeutics position peaked at $286K in Q1 2023.
  • 186 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.